TGFB1 and neoplasm: Currently, because the third isoform (TGF-β3) is hypothesized to have beneficial physiological effects in cancer (84), we are investigating the role of different TGF-β isoforms in the tumor setting and in conjunction with a cancer vaccine that contains a tumor antigen and a type I NKT agonist.